Finance

Lupus drug maker reports loss of $0.16 per share

Published in Drug Week, March 10th, 2006

Immunomedics, Inc., (IMMU), a biopharmaceutical company focused on developing monoclonal antibodies, reported revenues of $0.5 million and a net loss of $8.8 million, or $0.16 per share, for the second quarter of fiscal year 2006, which ended December 31, 2005.

This compares to revenues of $1.0 million and a net loss of $6.4 million, or $0.12 per share, for the same period last year. For the first half of the 2006 fiscal year, the company reported revenues of $0.9 million and a net loss of $17.4 million, or $0.32 per share. This compares to revenue of $2.1 million and a net loss of $10.6 million, or $0.20 per share, for the same period last year. The increase in net...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-03-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry